In the past 10 years, positron emission tomography (PET), usually with 18 F-fluoro-2-deoxy-
D-glucose (FDG), has become an important imaging modality in patients with lung cancer …

BACKGROUND: Positron-emission tomography (PET) shows tissue metabolic activity in the
form of the standard uptake value (SUV). This study examines the prognostic value of the …

Positron emission tomography in nonsmall cell lung cancer : Current Opinion in Pulmonary
Medicine Positron emission tomography in nonsmall cell lung cancer : Current Opinion in …

Objectives To investigate the role of PET in predicting the prognosis of resected stage IA non-
small cell lung cancer (NSCLC) and planning individualized therapeutic strategies. Methods …

The major utilization of clinical PET is in oncology, and oncologic PET utilizes FDG as the
radiopharmaceutical. FDG imaging demonstrates the increased metabolism by malignant …

Introduction Positron emission tomography (PET) scanning has gained increasing
application as a diagnostic and staging tool in the evaluation of lung cancer. Although PET …

Positron emission tomography (PET) has been in existence and continuously developing
over the past 20 years. In the last few years steady advances in the technology used for PET …

Objective of this work was to evaluate the role of 18F-fluorodeoxyglucose (FDG) positron-
emission tomography features as theranostic imaging biomarkers in non-small cell lung …

Integrated functional and anatomical imaging using positron emission tomography (PET)/CT
hybrid scanners has changed the diagnostic algorithm in non-small cell lung cancer …

Positron emission tomography (PET) constitutes a major advance in the diagnosis, staging,
prognostic assessment, and follow-up of lung cancer. However, it is not a magic bullet that …